{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:30:04Z","timestamp":1793853004255,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40122-025-00757-z","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T12:25:50Z","timestamp":1751027150000},"page":"1263-1278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gepants in Primary Care: A Targeted Approach to Acute and Preventive Treatment of Migraine"],"prefix":"10.1007","volume":"14","author":[{"given":"Maureen A.","family":"Moriarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Barch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"10100","key":"757_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211\u201359.","journal-title":"Lancet"},{"key":"757_CR2","volume-title":"Atlas of headache disorders and resources in the world 2011","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Atlas of headache disorders and resources in the world 2011. Geneva: World Health Organization; 2011."},{"key":"757_CR3","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"1","key":"757_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s10194-018-0910-y","volume":"19","author":"M Viana","year":"2018","unstructured":"Viana M, Sances G, Linde M, et al. Prolonged migraine aura: new insights from a prospective diary-aided study. J Headache Pain. 2018;19(1):77.","journal-title":"J Headache Pain"},{"issue":"2","key":"757_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553\u2013622.","journal-title":"Physiol Rev"},{"key":"757_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100053","volume":"7","author":"D Moreno-Ajona","year":"2020","unstructured":"Moreno-Ajona D, P\u00e9rez-Rodr\u00edguez A, Goadsby PJ. Small-molecule CGRP receptor antagonists: a new approach to the acute and preventive treatment of migraine. Med Drug Discovery. 2020;7:100053.","journal-title":"Med Drug Discovery"},{"issue":"6","key":"757_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/1060028020963574","volume":"55","author":"KR Joyner","year":"2021","unstructured":"Joyner KR, Morgan KW. Novel therapies in acute migraine management: small-molecule calcitonin gene-receptor antagonists and serotonin 1F receptor agonist. Ann Pharmacother. 2021;55(6):745\u201359.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"757_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40265-020-01264-5","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Ubrogepant: first approval. Drugs. 2020;80(3):323\u20138.","journal-title":"Drugs"},{"issue":"6","key":"757_CR9","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/jcm11061656","volume":"11","author":"D Moreno-Ajona","year":"2022","unstructured":"Moreno-Ajona D, Villar-Mart\u00ednez MD, Goadsby PJ. New generation gepants: migraine acute and preventive medications. J Clin Med. 2022;11(6):1656.","journal-title":"J Clin Med"},{"issue":"7","key":"757_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40265-020-01301-3","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Rimegepant: first approval. Drugs. 2020;80(7):741\u20136.","journal-title":"Drugs"},{"issue":"17 Supplement 2","key":"757_CR11","first-page":"4413","volume":"100","author":"S Hutchinson","year":"2003","unstructured":"Hutchinson S, Pavlovic J, Ailani J, et al. Rimegepant for the acute and preventive treatment of migraine in women: results from 4 randomized, placebo-controlled clinical trials (P9\u201312007). Neurology. 2003;100(17 Supplement 2):4413.","journal-title":"Neurology"},{"issue":"3","key":"757_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1089\/bfm.2021.0250","volume":"17","author":"TE Baker","year":"2022","unstructured":"Baker TE, Croop R, Kamen L, et al. Human milk and plasma pharmacokinetics of single-dose rimegepant 75\u00a0mg in healthy lactating women. Breastfeed Med. 2022;17(3):277\u201382.","journal-title":"Breastfeed Med"},{"issue":"1","key":"757_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-021-01644-5","volume":"82","author":"ED Deeks","year":"2022","unstructured":"Deeks ED. Atogepant: first approval. Drugs. 2022;82(1):65\u201370.","journal-title":"Drugs"},{"key":"757_CR14","unstructured":"Product monograph. QULIPTA\u00aeatogepant tablets. https:\/\/www.abbvie.ca\/content\/dam\/abbvie-dotcom\/ca\/en\/documents\/products\/QULIPTA_PM_EN.pdf. 2023. Accessed Oct 2024."},{"issue":"9","key":"757_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-023-01885-6","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S. Zavegepant: first approval. Drugs. 2023;83(9):825\u201331.","journal-title":"Drugs"},{"issue":"11","key":"757_CR16","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3390\/jcm10112468","volume":"10","author":"V Martin","year":"2021","unstructured":"Martin V, Hoekman J, Aurora SK, Shrewsbury SB. Nasal delivery of acute medications for migraine: the upper versus lower nasal space. J Clin Med. 2021;10(11):2468.","journal-title":"J Clin Med"},{"issue":"2","key":"757_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142\u20139.","journal-title":"N Engl J Med"},{"issue":"10200","key":"757_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase\u00a03, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737\u201345.","journal-title":"Lancet"},{"issue":"10268","key":"757_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase\u00a02\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51\u201360.","journal-title":"Lancet"},{"issue":"23","key":"757_CR20","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230\u201341.","journal-title":"N Engl J Med"},{"issue":"19","key":"757_CR21","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887\u201398.","journal-title":"JAMA"},{"issue":"8","key":"757_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695\u2013706.","journal-title":"N Engl J Med"},{"issue":"3","key":"757_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10\u00a0mg nasal spray for the acute treatment of migraine in the USA: a phase\u00a03, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209\u201317.","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"757_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/head.13305","volume":"58","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache. 2018;58(Suppl 1):33\u201347.","journal-title":"Headache"},{"issue":"2","key":"757_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bcp.12618","volume":"80","author":"L Edvinsson","year":"2015","unstructured":"Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80(2):193\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"757_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/joim.13506","volume":"292","author":"L Edvinsson","year":"2022","unstructured":"Edvinsson L. Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-successful translation of basic science to clinical practice. J Intern Med. 2022;292(4):575\u201386.","journal-title":"J Intern Med"},{"issue":"3","key":"757_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1212\/WNL.0b013e31822550e2","volume":"77","author":"EE Benarroch","year":"2011","unstructured":"Benarroch EE. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology. 2011;77(3):281\u20137.","journal-title":"Neurology"},{"issue":"13","key":"757_CR28","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1177\/0333102418786261","volume":"39","author":"K Messlinger","year":"2019","unstructured":"Messlinger K, Russo AF. Current understanding of trigeminal ganglion structure and function in headache. Cephalalgia. 2019;39(13):1661\u201374.","journal-title":"Cephalalgia"},{"issue":"3","key":"757_CR29","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0333102418774299","volume":"39","author":"LN Close","year":"2019","unstructured":"Close LN, Eftekhari S, Wang M, Charles AC, Russo AF. Cortical spreading depression as a site of origin for migraine: role of CGRP. Cephalalgia. 2019;39(3):428\u201334.","journal-title":"Cephalalgia"},{"issue":"9","key":"757_CR30","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1007\/s10072-022-06184-8","volume":"43","author":"C Altamura","year":"2022","unstructured":"Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F. Gepants \u2014 a long way to cure: a narrative review. Neurol Sci. 2022;43(9):5697\u2013708.","journal-title":"Neurol Sci"},{"key":"757_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.peptides.2019.04.012","volume":"116","author":"G Tringali","year":"2019","unstructured":"Tringali G, Navarra P. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. Peptides. 2019;116:16\u201321.","journal-title":"Peptides"},{"issue":"1","key":"757_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.tips.2018.11.005","volume":"40","author":"JJ Gingell","year":"2019","unstructured":"Gingell JJ, Hendrikse ER, Hay DL. New insights into the regulation of CGRP-family receptors. Trends Pharmacol Sci. 2019;40(1):71\u201383.","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"757_CR33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.tips.2007.10.005","volume":"28","author":"H Doods","year":"2007","unstructured":"Doods H, Arndt K, Rudolf K, Just S. CGRP antagonists: unravelling the role of CGRP in migraine. Trends Pharmacol Sci. 2007;28(11):580\u20137.","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"757_CR34","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s40263-022-00948-8","volume":"36","author":"N Karsan","year":"2022","unstructured":"Karsan N, Goadsby PJ. New oral drugs for migraine. CNS Drugs. 2022;36(9):933\u201349.","journal-title":"CNS Drugs"},{"issue":"1","key":"757_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/toxsci\/kfac051","volume":"188","author":"JL Woodhead","year":"2022","unstructured":"Woodhead JL, Siler SQ, Howell BA, Watkins PB, Conway C. Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling. Toxicol Sci. 2022;188(1):108\u201316.","journal-title":"Toxicol Sci"},{"issue":"23","key":"757_CR36","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1111\/bph.15657","volume":"178","author":"F Zobdeh","year":"2021","unstructured":"Zobdeh F, Ben Kraiem A, Attwood MM, et al. Pharmacological treatment of migraine: drug classes, mechanisms of action, clinical trials and new treatments. Brit J Pharmacol. 2021;178(23):4588\u2013607.","journal-title":"Brit J Pharmacol"},{"key":"757_CR37","unstructured":"American Migraine Foundation. Lifestyle changes for migraine management. https:\/\/americanmigrainefoundation.org\/resource-library\/lifestyle-changes-for-migraine\/. 2021. Accessed Oct 2023."},{"issue":"3","key":"757_CR38","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/head.13749","volume":"60","author":"H-C Diener","year":"2020","unstructured":"Diener H-C. The risks or lack thereof of migraine treatments in vascular disease. Headache J Head Face Pain. 2020;60(3):649\u201353.","journal-title":"Headache J Head Face Pain"},{"issue":"6","key":"757_CR39","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338\u201350.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"757_CR40","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/head.14824","volume":"64","author":"J Ailani","year":"2024","unstructured":"Ailani J, Gandhi P, Lalla A, et al. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine. Headache. 2024;64(10):1253\u201363.","journal-title":"Headache"},{"issue":"1","key":"757_CR41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s10194-024-01904-1","volume":"25","author":"W Laohapiboolrattana","year":"2024","unstructured":"Laohapiboolrattana W, Jansem P, Anukoolwittaya P, et al. Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis. J Headache Pain. 2024;25(1):194.","journal-title":"J Headache Pain"},{"issue":"10","key":"757_CR42","doi-asserted-by":"publisher","first-page":"e2128544","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"C-P Yang","year":"2021","unstructured":"Yang C-P, Liang C-S, Chang C-M, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(10):e2128544.","journal-title":"JAMA Netw Open"},{"key":"757_CR43","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241299377","author":"J Ailani","year":"2024","unstructured":"Ailani J, Lalla A, Halker Singh RB, et al. Benefit-risk assessment based on number needed to treat and number needed to harm: atogepant vs calcitonin gene-related peptide monoclonal antibodies. Cephalalgia. 2024. https:\/\/doi.org\/10.1177\/03331024241299377.","journal-title":"Cephalalgia"},{"issue":"7","key":"757_CR44","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339.","journal-title":"Headache"},{"key":"757_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/head.14523","author":"N Rosen","year":"2023","unstructured":"Rosen N, Mohajer A, Abraham L, et al. Reduction in barbiturate prescription fills and quantity dispensed following initiation of rimegepant treatment: a real-world administrative claims study. Headache. 2023. https:\/\/doi.org\/10.1111\/head.14523.","journal-title":"Headache"},{"issue":"4","key":"757_CR46","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/head.14062","volume":"61","author":"CC Chiang","year":"2021","unstructured":"Chiang CC, Arca KN, Dunn RB, et al. Real-world efficacy, tolerability, and safety of ubrogepant. Headache. 2021;61(4):620\u20137.","journal-title":"Headache"},{"issue":"1","key":"757_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-023-01622-0","volume":"24","author":"MA Adams","year":"2023","unstructured":"Adams MA, Hutchinson S, Engstrom E, et al. Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study. J Headache Pain. 2023;24(1):102.","journal-title":"J Headache Pain"},{"issue":"18 Supplement","key":"757_CR48","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1212\/WNL.98.18_supplement.1167","volume":"98","author":"AR Shewale","year":"2022","unstructured":"Shewale AR, Weijie P, Michael LR, et al. Real-world effectiveness of ubrogepant among participants with prior treatment failure: subgroup analysis from the UNIVERSE study (P12\u20132.001). Neurology. 2022;98(18 Supplement):1167.","journal-title":"Neurology"},{"issue":"13","key":"757_CR49","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1021\/acs.jmedchem.9b01810","volume":"63","author":"GM Dubowchik","year":"2020","unstructured":"Dubowchik GM, Conway CM, Xin AW. Blocking the CGRP pathway for acute and preventive treatment of migraine: the evolution of success. J Med Chem. 2020;63(13):6600\u201323.","journal-title":"J Med Chem"},{"issue":"4","key":"757_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027701","volume":"9","author":"SY Lee","year":"2019","unstructured":"Lee SY, Lim JS, Oh DJ, Kong IG, Choi HG. Risk of ischaemic stroke in patients with migraine: a longitudinal follow-up study using a national sample cohort in South Korea. BMJ Open. 2019;9(4):e027701.","journal-title":"BMJ Open"},{"issue":"10","key":"757_CR51","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1046\/j.1526-4610.2001.01189.x","volume":"41","author":"SD Silberstein","year":"2001","unstructured":"Silberstein SD, McCrory DC. Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache J Head Face Pain. 2001;41(10):953\u201367.","journal-title":"Headache J Head Face Pain"},{"issue":"5","key":"757_CR52","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1212\/WNL.0000000000009324","volume":"95","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Buse DC, Friedman BW, et al. Characterizing opioid use in a US population with migraine: results from the CaMEO study. Neurology. 2020;95(5):e457\u201368.","journal-title":"Neurology"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00757-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-025-00757-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-025-00757-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:51:57Z","timestamp":1757206317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-025-00757-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1007\/s40122-025-00757-z","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carol A. Barch served as a consultant for AbbVie and Aptar, Maureen A. Moriarty served as a consultant for AbbVie. Carol A. Barch and Maureen A. Moriarty are on the AbbVie and Pfizer advisory board (March 2024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}